readthroughSign in
Nov 12, 2026Weekly roundupUpdated

BMS's two Phase 3 autism irritability trials of KarXT + KarX-EC remain in recruiting status

Bristol-Myers Squibb's parallel Phase 3 studies testing KarXT plus KarX-EC for irritability tied to autism spectrum disorder continue recruiting, with no new status changes posted.

No new trials or results were posted for Bristol-Myers Squibb this week; both previously listed Phase 3 autism irritability studies remain active.

  • NCT07284745 (CN012-0044), a Phase 3, multicenter, randomized, double-blind, placebo-controlled study assessing efficacy, safety, tolerability, and pharmacokinetics of KarXT plus KarX-EC in children and adolescents aged 5 to 17 years with irritability associated with autism spectrum disorder1, is recruiting. The study has an estimated enrollment of 176 participants1 and its primary outcome is change from baseline in the Aberrant Behavior Checklist Irritability (ABC-I) Score at Week 81, running at 41 sites in four countries: United States, Australia, Canada, Puerto Rico1.
  • NCT07285798 (CN012-0045), a Phase 3, multicenter, randomized, double-blind, placebo-controlled study assessing efficacy, safety, and tolerability of KarXT plus KarX-EC in the same pediatric and adolescent population with autism-related irritability2, is also recruiting. It shares the same estimated enrollment of 176 participants2 and primary endpoint of change from baseline in the Aberrant Behavior Checklist Irritability (ABC-I) Score at Week 82, but spans 67 sites in 10 countries, including United States, France, Germany, Hungary, India, Japan, Poland, Puerto Rico, Romania, and Spain2.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.